Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CytomX Therapeutics Inc CTMX

Healthcare Biotechnology
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic... see more

Recent & Breaking News (NDAQ:CTMX)

CytomX Therapeutics Announces New Employment Inducement Grants

GlobeNewswire August 17, 2021

CytomX Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire August 5, 2021

CytomX Therapeutics Announces Multiple Publications on Pacmilimab (CX-072), a Conditionally Activated Inhibitor of Programmed Death-Ligand 1 (PD-L1)

GlobeNewswire August 4, 2021

CytomX Therapeutics to Present at Upcoming August Investor Conferences

GlobeNewswire August 2, 2021

CytomX Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021

GlobeNewswire July 29, 2021

CytomX Therapeutics Announces Publication of First-in-Human Data for CX-2029 in Clinical Cancer Research

GlobeNewswire June 21, 2021

CytomX Therapeutics to Present at Jefferies Virtual Healthcare Conference

GlobeNewswire May 27, 2021

CytomX Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire May 6, 2021

CytomX Therapeutics to Announce First Quarter 2021 Financial Results on May 6, 2021

GlobeNewswire April 29, 2021

CytomX Therapeutics Announces New Employment Inducement Grants

GlobeNewswire April 14, 2021

CytomX Therapeutics to Host Virtual Investor Event on April 7, 2021

GlobeNewswire March 24, 2021

CytomX Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

GlobeNewswire February 24, 2021

CytomX Therapeutics to Present at Upcoming March Virtual Investor Conferences

GlobeNewswire February 22, 2021

CytomX Therapeutics Announces New Employment Inducement Grant

GlobeNewswire February 19, 2021

CytomX Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021

GlobeNewswire February 17, 2021

CytomX Therapeutics to Present at Guggenheim Healthcare Talks 2021 Oncology Day

GlobeNewswire February 4, 2021

UPDATE - CytomX Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire February 3, 2021

CytomX Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire February 3, 2021

CytomX Therapeutics Announces Closing of Public Offering of Common Stock

GlobeNewswire January 26, 2021

CytomX Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

GlobeNewswire January 20, 2021